Articles

ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease

Department of Pharmacology, University of Illinois College of Medicine, Chicago, IL, USA
Department of Pharmacology, University of Illinois College of Medicine, Chicago, IL, USA
Department of Pharmacology, University of Illinois College of Medicine, Chicago, IL, USA
Department of Pharmacology, University of Illinois College of Medicine, Chicago, IL, USA
Department of Pharmacology, University of Illinois College of Medicine, Chicago, IL, USA
ArQule, Inc., Burlington, MA, USA
ArQule, Inc., Burlington, MA, USA
ArQule, Inc., Burlington, MA, USA
Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
Section of Hematology/Oncology, University of Illinois College of Medicine, Chicago, IL, USA;Comprehensive Sickle Cell Center, University of Illinois College of Medicine, Chicago, IL, USA
Department of Pharmacology, University of Illinois College of Medicine, Chicago, IL, USA
Vol. 102 No. 2 (2017): February, 2017 https://doi.org/10.3324/haematol.2016.151159